EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the first quarter of 2025.
VERONA is a phase II trial evaluating the company's lead investigational product Duravyu in diabetic macular edema patients previously treated with a standard-of-care FDA-approved anti-VEGF treatment, like intravitreal Aflibercept. Duravyu delivers Vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), formulated in a solid bioerodible insert using EyePoint's proprietary sustained-release Durasert E technology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.